Oral Formulation Focus Frontida BioPharm operates as a minority-owned contract development and manufacturing organization focused on oral formulations. With a strong track record of FDA-compliant quality and a collaborative development approach, they appeal to mid-market biotech and pharma clients seeking end-to-end development and manufacturing support.

Abuse Deterrent Testing CAT.ONE in vitro testing and evaluation for abuse-deterrent formulations provides a differentiated offering that can help clients meet regulatory requirements for pain management and CNS products while expanding testing services across product development stages.

Containment Solutions Lancs Industries collaboration highlights Frontida's containment and worker-safety capabilities, presenting an upsell path to clients during process development and scale-up who need robust containment equipment or protective systems.

Acquisition Synergy The Adare acquisition indicates access to a broader network of CDMOs and potential cross-sell opportunities with Adare and Frontage client bases, enabling joint development or manufacturing programs and increasing win potential.

Strategic Growth The company’s minority-owned status, US footprint, and connections to a broader network offer growth paths through supplier-diversity programs, partnerships, and geographic expansion into additional pharmaceutical and biotech programs.